Galderma's Restylane Volyme has demonstrated high effectiveness and satisfaction in a clinical trial evaluating temple hollowing correction in Chinese patients. Temple volume loss is a distinct aesthetic concern in East Asian populations—more pronounced than in Western cohorts—and the study validates Volyme's crosslinked hyaluronic acid formulation for this specific anatomical application.
Injectables
Restylane Volyme Wins China Temple Hollowing Study
Galderma filler shows high efficacy and safety in Chinese patient cohort.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Volyme shows high efficacy in Chinese patients with temple hollowing.
Volyme's rheology (G' of 2,500 Pa) makes it suitable for structural support in low-mobility zones like the temple, where shear forces are minimal and longevity matters. The China data is significant because it gives Galderma localized clinical evidence for regional marketing and physician training—a requirement for market penetration in regulated Asian markets. For U.S. practices, this reinforces Volyme's positioning in the Restylane portfolio as the volumizer for structural correction, distinct from Lyft (cheek/midface) and Kysse (lips). Expect Galderma to leverage this study in sales conversations around temple and orbital rim treatments.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.